Eli Lilly's Emgality becomes third CGRP inhibitor approved in US for #migraine https://www.firstwordpharma.com/node/1593879 $LLY
More From BioPortfolio on "Eli Lilly's Emgality becomes third CGRP inhibitor approved in US for #migraine https://www.firstwordpharma.com/node/1593879 $LLY"